Nobel Biocare vs Straumann — an honest comparison

Declaring the interest first

This site is built around Nobel Biocare systems and its clinical partner uses them. You should read what follows knowing that, and you should be suspicious of any conclusion that happens to flatter the party writing it.

So here is the conclusion in advance, and it does not flatter anybody: on the published evidence, neither manufacturer can be shown to outlast the other in a given patient. Anyone claiming otherwise — in either direction — is going past what the literature supports.

What can be discussed usefully is what differs in practice, and which questions matter more than this one.

What they have in common

More than most comparisons admit.

Both are long-established European manufacturers with decades of clinical use. Both hold the regulatory clearances that matter — FDA 510(k) in the United States, CE marking under the EU medical device regime, manufacturing quality systems to ISO 13485. Both are available in most countries, which matters enormously for getting a component in ten years.

Both have substantial published literature behind them, including independent series rather than only manufacturer-sponsored work. And both sit inside the general picture the evidence gives for modern implants: a 10-year survival estimate of 96.4% across systems.

If you are choosing between these two, you have already narrowed to a shortlist where the brand is not your biggest risk.

Where they actually differ

Range and philosophy

Nobel Biocare’s catalogue is broad and deliberately varied: a condensing tapered design, a parallel-walled system positioned for indications from single tooth to full arch, a tapered straightforward option, and N1 — which the manufacturer defines as a complete system, with its own site-preparation protocol rather than an implant that drops into an existing workflow.

Straumann’s range is likewise extensive and its own designs have real followings, particularly for particular bone types and surgical preferences.

The practical difference is not “wider is better”. It is that a clinic committed to one manufacturer should have enough options within it to fit your anatomy without compromise. Both ranges clear that bar.

Full-arch concepts

Nobel Biocare defines All-on-4 as a named treatment concept with its own protocol and components, and there is an unusually long body of published follow-up attached to it. If a full-arch fixed bridge is what you need, that documented lineage is a genuine consideration.

Straumann has its own full-arch approaches, and clinicians achieve equivalent results with them. The difference is less about capability than about which protocol a given surgeon works to confidently.

Surfaces and connections

Both invest heavily here and both publish on it. The honest patient-facing summary is that surface technology influences how bone attaches at the margins, that this is a real area of engineering, and that it is not where your outcome will be decided.

Anyone selling you a surface as the reason to choose a brand is selling the least decisive variable in the treatment.

What the evidence does not say

Worth being explicit, because this is where comparison pages usually overreach.

There is no head-to-head randomised trial placing one manufacturer against the other in comparable patients and following them for a decade. It would need thousands of participants, ten-plus years and a funder with no stake in the answer. It does not exist and probably never will.

What exists instead is a large number of studies on each system separately, with different populations, different follow-up periods and different definitions of success. Those cannot be subtracted from one another to produce a winner, however confidently a website presents the arithmetic.

So when you read “brand X has a 98.2% survival rate and brand Y has 97.6%”, you are reading two unrelated studies placed side by side. That is not a comparison. It is a layout.

What matters more than this choice

In rough order:

1. Who is placing it, and who is restoring it. The position of the implant relative to the tooth that must sit on it affects outcome more than the fixture’s manufacturer. Which is why the surgical and restorative sides are planned together at Taki Dent rather than in sequence.

2. Whether the site was assessed on a CBCT scan. Bone width is invisible on a panoramic radiograph, and width is what most often changes the plan.

3. Whether the loading decision was made on a measurement. Stability read during surgery, not promised beforehand.

4. Whether anyone looks at it again. Implants need maintenance and review; problems found early are manageable, problems found late frequently are not.

5. Whether you can get a component in ten years. Both manufacturers score well here, which is a genuine argument for either over a lesser-known brand.

Only after all five does the choice between these two names start to move the outcome.

How the comparison is usually presented, and why to distrust it

Search this question and you will meet three recurring formats. All three are misleading in different ways, and recognising them saves time.

The specification table. Thread pitch, connection type, surface designation, available diameters, laid out side by side. It looks rigorous and answers nothing, because the numbers only acquire meaning against a particular jaw. Two implants with identical specifications behave differently in soft bone.

The survival-rate face-off. Brand X at 98.2%, brand Y at 97.6%, presented as though the difference means something. As established above, those figures come from separate studies with different patients, different follow-up periods and different definitions of success. Placing them in adjacent columns does not make them comparable.

The clinic’s own verdict. Almost always resolving in favour of whatever that clinic stocks. Not necessarily dishonest — a surgeon who has used one system for fifteen years genuinely believes in it, and has reason to — but it is a preference presented as a finding.

The format worth reading is the one that says what each design does, in which situations, and admits where the evidence stops. That is harder to write and less satisfying to read, which is presumably why it is rarer.

What a fair head-to-head would require

It is worth spelling out what is missing, because the absence explains everything above.

You would need several thousand patients randomised between the two manufacturers, matched for bone quality, site, smoking status, systemic health and bite. You would need the same surgical team, or enough teams to cancel out operator effect. You would need consistent success criteria applied identically to both arms. And you would need ten years minimum, since most differences worth knowing about appear late rather than early.

The cost would be enormous and the funder would necessarily be one of the manufacturers, an independent body with no commercial interest, or a public research programme. None has done it.

That is not a scandal — it is the same reason head-to-head trials are rare across medical devices generally. But it means the honest position is agnosticism between two well-documented systems, and any site expressing certainty is expressing marketing.

When the answer is “whichever your clinic knows”

This sounds like a dodge and is actually the most evidence-consistent advice on the page.

A surgeon working within a system they use every week — whose protocol they know, whose components they stock, whose behaviour in soft bone they have seen a hundred times — will produce better results than the same surgeon using an unfamiliar system with a marginally better specification.

Familiarity is a clinical variable. It never appears in a brochure and it routinely outweighs the differences that do.

If you already have one and are adding another

A specific situation worth covering, because it comes up often and has a clear answer.

If you have existing implants from one manufacturer and need another elsewhere in the mouth, there is no clinical requirement for the new one to match. They are independent units; they do not interact. A different system in a different site is entirely normal.

What does argue for matching is practical rather than biological: one manufacturer means one set of components, one set of tools at your maintenance appointments, and one supplier to reach if something needs replacing. For a dentist looking after you long-term, that is genuinely simpler.

Where the new implant will be joined to an existing one — carrying a shared bridge — matching becomes more important, because the restorative components have to work together.

So: different site, either is fine and convenience favours matching. Connected to existing work, ask the question directly.

The questions to ask instead

1. Which system do you use most, and why?
2. What would make you choose something else for my case?
3. Where does my dentist at home source components in ten years?
4. What am I given in writing about what was placed?

Ask those four and the brand question mostly answers itself — and you will have learned considerably more about the clinic than about the catalogue.

A final diagnosis and treatment plan can only be confirmed after clinical examination and appropriate radiological assessment. If you would like the reasoning applied to your own case rather than to a comparison table, send a recent panoramic radiograph or CBCT scan and the clinical team at Taki Dent will set out what your anatomy actually calls for.